1-13 of 13
Akshay Sudhindra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Free
Marc Hoffmann, Julio Chavez, Jason Westin, Judit Jørgensen, Javier Munoz, Cecilia Carpio, Guilherme Perini, Emmanuel Bachy, Victoria Campbell, Caroline Hasselbalch Riley, Franck Morschhauser, Daniel Morillo, Alev Akyol, Berengere De Moucheron, Michael Pourdehnad, Akshay Sudhindra, Soraya Carrancio, Jessica Voetsch, Gang Yang, Serena Perna, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 479.
https://doi.org/10.1182/blood-2025-479
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Free
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos
Journal: Blood
Blood (2025) 146 (Supplement 1): 476.
https://doi.org/10.1182/blood-2025-476
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Free
Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 1006.
https://doi.org/10.1182/blood-2025-1006
Published: 2025
Journal Articles

Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Free
Koji Izutsu, Noriko Fukuhara, Makoto Sugaya, Yuichi Baba, Jin Hayakawa, Mitsufumi Nishio, Alev Akyol, Akshay Sudhindra, Kenji Ishitsuka
Journal: Blood
Blood (2024) 144 (Supplement 1): 3123.3.
https://doi.org/10.1182/blood-2024-203202
Published: 2024
Journal Articles

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Free
Marc Hoffmann, Theodoros Vassilakopoulos, Javier Munoz, Jason R. Westin, Maria Bouzani, Wojciech Jurczak, Michał Kwiatek, Alejandro Berkovits, Tai-Chung Huang, Akshay Sudhindra, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Grzegorz S. Nowakowski
Journal: Blood
Blood (2024) 144 (Supplement 1): 1742.2.
https://doi.org/10.1182/blood-2024-203185
Published: 2024
Journal Articles

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Free
Jose C. Villasboas Bisneto, Pier Luigi Zinzani, Andrew J. Davies, Robert Kridel, Guilherme Fleury Perini, Parth Rao, Joanna Mikita-Geoffroy, Akshay Sudhindra, Charalambos Andreadis
Journal: Blood
Blood (2024) 144 (Supplement 1): 4422.2.
https://doi.org/10.1182/blood-2024-203181
Published: 2024
Journal Articles

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

Free
Arnaud Amzallag, Tara Basavanhally, Jason R. Westin, Marc Hoffmann, Theodoros P. Vassilakopoulos, Javier Munoz, Grzegorz S. Nowakowski, Floriane Boucaud, Matt Stokes, Akshay Sudhindra, Anita K. Gandhi, Mark Kaplan
Journal: Blood
Blood (2024) 144 (Supplement 1): 579.
https://doi.org/10.1182/blood-2024-203135
Published: 2024
Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Free
Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez
Journal: Blood
Blood (2024) 144 (Supplement 1): 869.
https://doi.org/10.1182/blood-2024-203163
Published: 2024
Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Free
Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot
Journal: Blood
Blood (2024) 144 (Supplement 1): 3018.
https://doi.org/10.1182/blood-2024-203131
Published: 2024
Journal Articles

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Free
Mark Kaplan, Tara Basavanhally, Yumi Nakayama, Charalampos Kyriakopoulos, Arnaud Amzallag, Argyrios Gkasiamis, Arpankumar Patel, Akshay Sudhindra, Grzegorz S. Nowakowski, Jason Westin, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1631.
https://doi.org/10.1182/blood-2023-180231
Published: 2023
Journal Articles

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Free
Matthew E Stokes, Kerstin Wenzl, C. Chris Huang, Maria Ortiz Estevez, Matthew J. Maurer, Nicholas Stong, Patrick Hagner, Yumi Nakayama, Chih-Chao Hsu, Samuel A Danziger, Fadi Towfic, Rebecca L. King, Joel S. Parker, Brian K. Link, Susan L. Slager, Vivekananda Sarangi, Yan Asmann, Joseph P. Novak, Akshay Sudhindra, Stephen M. Ansell, Thomas M. Habermann, Grzegorz S. Nowakowski, James R. Cerhan, Anne J. Novak, Anita K. Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3548–3550.
https://doi.org/10.1182/blood-2022-170228
Published: 2022
Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Free
Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2828.
https://doi.org/10.1182/blood-2019-123279
Published: 2019
Journal Articles

Risk of Patients Developing Post-Transplant Lymphoproliferative Disorder within the First Year after an Allogeneic Hemopoietic Stem Cell Transplant, 2011 to 2016: A US Claims Database Analysis

Free
Arie Barlev, PharmD, Hairong Xu, MD PhD, Nicole Fulcher, MA, Crystal Watson, MS, Ila Sruti, MPH, Akshay Sudhindra, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5840.
https://doi.org/10.1182/blood-2018-99-113598
Published: 2018